SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kopin Corp. engages in the development, manufacture and sale of wearable technologies which include components and systems. Its portfolio includes AMLCD, LCOS displays, OLED displays, ASIC, backlights, and optical lenses. The firm uses semiconductor material technology to design, manufacture and market its component products for use in military, enterprise and consumer electronic applications, training and simulation equipment and 3D metrology equipment. The company was founded by John C.C. Fan on April 23, 1984 and is headquartered in Westborough, MA.

Kopin Corp.

Kopin Corp

Kopin Corp is experiencing significant market interest and a trading halt following a string of major defense contracts and a high-profile partnership to develop AI-focused optical interconnect technology. The community is buzzing over the potential for a massive short squeeze and the strategic pivot toward high-growth AI infrastructure, with many investors holding long-term positions in anticipation of further institutional adoption.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors digest a Financial Times report that activist investor Nelson Peltz's Trian Fund Management is seeking financing for a potential take-private bid for the company. Community discussion is heavily focused on the high short interest and the potential for a significant squeeze, with many retail investors debating a fair buyout price and expressing frustration over the company's lack of a permanent CEO and recent stock price volatility.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is experiencing significant investor interest driven by its shift from research to the commercial deployment of its Dirac-3 platform and strategic photonic hardware acquisitions. The community is actively discussing the stock's potential for a short squeeze, fueled by high short interest and bullish institutional positioning, while debating whether current revenue levels can support its multi-billion dollar market valuation.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors digest a strong earnings beat and a significant guidance hike, with the community closely tracking the geopolitical impact of the Strait of Hormuz blockade on long-term supply constraints. Bullish sentiment remains high among retail holders who see the stock as an undervalued energy play, despite ongoing volatility driven by macro-economic uncertainty and conflicting reports regarding potential diplomatic resolutions in the region.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors debate the sustainability of its valuation and high cash burn against massive growth in bookings, sparking an intense tug-of-war between retail bulls anticipating future utility and bears expecting a pullback. The conversation is heavily focused on the company's competitive position in annealing versus gate-model systems and speculation surrounding upcoming financial results.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention from investors as anticipation builds around the upcoming SpaceX IPO, with community members actively debating the fund's net asset value and exposure to private tech leaders like Anthropic. While some investors remain cautious about the fund's premium to its holdings and recent share offerings, others are highlighting the potential for a short squeeze due to the limited float and high interest in pre-IPO access.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors weigh an earnings revenue miss against the company's reaffirmed full-year satellite launch cadence and ongoing infrastructure build-out. The community remains deeply divided, with bulls prioritizing long-term growth and government contract potential, while bears are expressing concern over cash burn, launch dependencies, and historical execution challenges.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending as investors position for the Cerebras Systems IPO and anticipate potential spillover effects from the broader AI infrastructure rally. The community is actively discussing the company's valuation gap relative to its role as a key Cerebras partner, with many closely watching for upcoming earnings and the potential for a short squeeze given the stock's low float and high institutional ownership.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is trending as investors digest a major governance update, while the community remains sharply divided between those betting on aggressive short squeezes and others labeling it a high-risk Chinese pump-and-dump scheme. Intense volatility and circuit breaker halts are driving heavy daily volume as traders debate the sustainability of recent price swings and potential institutional involvement.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark shares are experiencing heightened volatility as the community debates the timing of an anticipated AI infrastructure deal and its shift toward high-performance computing. While some investors are bullish on the company's power capacity and Bitcoin treasury as long-term catalysts, others are expressing frustration over the lack of a concrete hyperscale contract and the impact of recent quarterly earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Raymond James🏁 $TSHA Strong Buy/$13 
$NGNE $ACAD $ALPMY  
Raymond James said: 
Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. 
 
Raymond James added:

Peter Quick

Glide

Warren Collins

avalon E

Citizens reiterated $TSHA Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. 
$NGNE $ACAD $ALPMY 
Citizens JMP added: 
A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett 
gene therapy competitor. 
 
We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: 
Overall, both TSHA &amp; NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. 
 
Based on the more involved procedure required for 
ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.

StockTwits Web

Taysha Gene Therapies Inc

Neurogene Inc

Acadia Pharmaceuticals Inc

ASTELLAS PHARMA/ADR

Quantumup

Cantor reit $TSHA OW13 
$NGNE $ACAD 
Neurogene (NGNE, NC) reported updated Phase 1/2 data for its ICV-administered gene therapy NGN-401 in Rett syndrome (rare neurodevelopmental disorder). From our conversations, we believe investors have spent more time focusing on key differences between the approaches, although there have also been questions about how to interpret cross-data comparisons with Taysha&#39;s TSHA-102 (intrathecally administered AAV9-based gene therapy). 
 
NGNE shares closed -15% today (vs. -8% for TSHA), which we believe could be in part related to some of the treatment-related AEs that were disclosed in NGNE&#39;s release. 
 
While we believe both companies are assessing natural history datasets to understand what is deemed a milestone, skill, etc., we don&#39;t fully appreciate or understand what analysis NGNE evaluated their data against. Nor do we fully understand the statistical analysis plan NGNE has put into place to fully appreciate what is deemed a &quot;responder&quot; in their pivotal trial.

  
Raymond James said: 
Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. 
 
Raymond James added: